University of Glasgow

The PHOENIX Study, one of the largest pharmacogenomics trials globally, will recruit up to 4,000 patients over two years to investigate how genetic profiles affect responses to 60 commonly prescribed NHS medications.

A large meta-analysis of 167 studies across eight vertebrate species found that rapamycin extends lifespan as effectively as dietary restriction and intermittent fasting.

Post-hoc analysis of Lilly's SURPASS-3 trial reveals tirzepatide treatment in type 2 diabetes patients leads to muscle volume changes proportional to weight loss, with greater than expected reductions in muscle fat infiltration.

The University of Glasgow's Living Laboratory for Precision Medicine has partnered with myDNA to generate real-world evidence supporting pharmacogenomics adoption in healthcare systems.

Research published in the journal Heart reveals that individuals who walk at a brisk pace (over 4 mph) have a 43% lower risk of developing abnormal heart rhythms compared to slower walkers.

Stellaromics has secured significant funding to advance their Pyxa platform, a revolutionary 3D spatial transcriptomics technology that enables comprehensive analysis of thick tissue sections.

Researchers have genetically engineered *Salmonella* to target and combat bowel cancer cells, potentially turning a disease-causing bacterium into a therapeutic agent.

A new study reveals that torasemide, a loop diuretic, significantly reduces blood pressure in hypertension patients with a specific UMOD gene variant.